Merck KGaA verhandelt Milliardendeal mit US-Tumorspezialisten
Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks ...
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company’s common stock ...
AOL6d
Analysts Defend Merck Amid Investor Concerns Over Weak Guidance
On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...
Wall Street Journal7d
Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
Merck MRK0.14%increase; green up pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...
ABC News8d
Merck 2025 sales forecast underwhelms as it pauses Gardasil sales in China
For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion ...
appliedclinicaltrialsonline12d
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the ...
Merck stock price target lowered to $95 by Bernstein SocGen
Bernstein SocGen Group has revised its price target for Merck (NYSE:MRK) shares, bringing it down to $95 from the previous $110 while maintaining a Market Perform rating. Analyst Courtney Breen cited ...